Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...

We recently compiled a list of Morgan Stanley’s Best Stock Picks: 15 Stocks To Own For 2025. In this article, we are going to ...

Lilly clearly has an abundance of growth drivers -- and the list includes more than Mounjaro, Zepbound, and the six drugs ...

Company is investing $2.8bn in two Irish plants to produce its in-demand weight loss drugs and a new Alzheimer’s therapy ...

Eli Lilly will invest $1.8 billion to boost manufacturing for its newly approved Alzheimer's drug and highly popular weight ...

How Eli Lilly’s Next 5 Years Could Play Out We expect Eli Lilly’s P/E ratio in 2025 to be 60 with an EPS of $19.11, resulting in a price target of $1140.00 This prediction is based on strong ...

Full-service independent pharmaceutical marketing and communications agency RevHealth, a 2024 MM+M Agency 100 honoree, named former 21Grams and Wunderman Thompson Health exec William Martino as chief ...

Headlines,Novo Nordisk experienced a decline in stock value after recent news from its lab.,Eli Lilly, (NYSE:LLY),and Viking ...

Drugmaker Eli Lilly named Lucas Montarce as chief financial officer, filling a vacancy left by the departure of Anat Ashkenazi, who joined Google’s parent company Alphabet as CFO earlier this year.

Feel free to distribute or cite this material, but please credit OpenSecrets. For permission to reprint for commercial uses, such as textbooks, contact OpenSecrets: [email protected] ...

Eli Lilly (NYSE: LLY) stands atop the biopharmaceutical ... Lilly's pipeline features several late-stage candidates that should have major commercial potential. The company is evaluating ...